Open AccessPaediatric clinical research from the perspective of hospital pharmacists from F rance and C anada
Author(s) -
Guérin Aurélie,
Tanguay Cynthia,
Lebel Denis,
ProtLabarthe Sonia,
Bourdon Olivier,
Bussières JeanFrançois
Publication year - 2014
Publication title -
international journal of pharmacy practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.42
H-Index - 37
eISSN - 2042-7174
pISSN - 0961-7671
DOI - 10.1111/ijpp.12099
Subject(s) - medicine , family medicine , pharmacy , clinical trial , clinical pharmacy , descriptive statistics , hospital pharmacy , pediatrics , statistics , mathematics , pathology
Objectives To compare pharmacy support for paediatric research services in F rance and C anada and to describe the perception of pharmacists and rank the paediatric clinical research issues. Methods This was a cross‐sectional descriptive study. All paediatric hospitals from C anada and the main hospitals from F rance were contacted. A survey was conducted from M ay– S eptember 2012. Descriptive statistics were performed. Key findings Results from 11 paediatric hospitals in C anada (11/12, 92%) and 11 (11/18, 61%) in F rance were obtained. There was a similar number of ongoing paediatric clinical trials per hospital in F rance versus C anada (38 (10–81) versus 20 (4–178)). A lower number of pharmacists per hospital was observed in F rance (17 (11.5–35) versus 45 (18.9–76.8)), but a similar number of pharmacists were assigned to clinical trials (1.5 (1–3) versus 1.9 (0.2–17.4)). Institutional protocols represented the majority of paediatric clinical trials in F rance (61% (14–100) versus 25% (0–100)). Similar pharmacy support services were offered, but the majority of F rench respondents also offered help for institutional protocol development (91 versus 50% P = 0.063). The main issues associated with paediatric clinical research were absence of financial interest from the pharmaceutical industry, prohibitive cost versus profit ratio, small patient cohorts and the non‐availability of the appropriate drug formulations. Conclusions Difficulties related to pharmaceutical compounding were identified as the main hindrance to paediatric clinical research; particular attention should be paid to these details when setting up a paediatric trial.